AI Transparency Report
The Amyloidosis Foundation demonstrates consistent financial health with assets generally exceeding liabilities and a stable revenue stream over the past decade. While revenue has fluctuated, ranging from $535,162 in 2023 to $861,106 in 2014, the organization has maintained a positive net asset position, reaching $1,050,511 in 2023. The organization's spending efficiency appears strong, particularly given its reported 0% officer compensation across all available filings, suggesting a volunteer-driven or very lean administrative structure for leadership. This lack of paid executive compensation is a significant indicator of efficient use of donor funds.
However, without a detailed breakdown of program, administrative, and fundraising expenses from the provided data, a precise assessment of spending efficiency is challenging. The consistent growth in assets, from $612,000 in 2016 to over $1 million in recent years, indicates sound financial management and an ability to build reserves. The organization's transparency is commendable in its consistent filing of IRS Form 990s, with 14 filings available, providing a long historical view of its financial operations. Further transparency could be enhanced by publicly detailing the allocation of expenses across its core functions.